“This course covered an impressive breadth of material while ensuring objectives for each learning domain were manageable. The entire course was very well organized and the instructors were both accessible to students and passionate about their work. As a research associate with a public health background, I was particularly inspired by course modules that covered topics outside my professional purview (e.g. immunology, methods in correlates of protection). The two-week intensive course has expanded my academic interests and I will use this learning to shape next steps in my career” Rika Moorhouse, Ottawa

“The course was a fantastic opportunity to experience the full breadth of research in vaccines through contact with leading scientists and peers working in the area. In addition, having participants from all over the globe gave the course a unique mix of experiences and perspectives that enriched learning and skill acquisition. The skills I gained from the course were of immediate practical use in my work on the impact of the pneumococcal conjugate vaccine in Kenya. Insights I gained during the course are guiding me towards developing a research question in the field of measles epidemiology and measles vaccine policy. Attending the course also helped me develop important contacts in the field of vaccine epidemiology.” Kenneth Munge, Nairobi

“This course was really comprehensive for both regulatory bodies and industry as well. It helped me to understand the methods of conducting vaccine studies which are different than regular medicinal products. Also, the materials are very useful to evaluate all studies that relate to vaccines and I still use them, especially during my routine work.” Thamir M Alshammari, Riyadh

"The course is very relevant for vets given that the epidemiological assessment techniques are the same, regardless of disease. Some of the examples are veterinary (Paul Fine likes to add some!) Regulation of veterinary medicines is very similar in process to that of human drugs and the types of studies presented should be the same. Often the scale is smaller, but the course will help highlight the risks from this. For my work, where I am considering how we could trial a TB vaccine in cattle, the course has helped me understand key issues of interest to the EU and to stakeholders, namely how do we know if the vaccine will make a difference to disease epidemiology?" Eleanor Brown, UK